| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8344122 | Molecular Genetics and Metabolism | 2012 | 5 Pages |
Abstract
Conclusions: In the SPG11 patient with extrapyramidal symptoms, a trial of l-dopa/carbidopa and sapropterin and/or evaluation of cerebrospinal fluid neurotransmitters should be considered.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Adeline Vanderver, Davide Tonduti, Sarah Auerbach, Johanna L. Schmidt, Sumit Parikh, Gordon C. Gowans, Kelly E. Jackson, Pamela L. Brock, Marc Patterson, Michelle Nehrebecky, Rena Godfrey, Wadih M. Zein, William Gahl, Camilo Toro,